Feasibility of using alternative swabs and storage solutions for paired SARS-CoV-2 detection

and microbiome analysis in the hospital environment

Running Title: Alternative swabs for COVID-19 screening and microbiome analysis

Jeremiah J. Minich[1], Farhana Ali[2], Clarisse Marotz[3], Pedro Belda-Ferre[3], Leslie Chiang[4], Justin P. Shaffer[3],

Carolina S. Carpenter[5], Daniel McDonald[3], Jack Gilbert1[1,3,5], Sarah M. Allard[3], Eric E Allen[1,5,6], Rob Knight[3,5,7,8],

Daniel A. Sweeney[9], Austin D. Swafford[5#]

1. Marine Biology Research Division, Scripps Institution of Oceanography, University of California San

Diego, La Jolla, CA, USA.

2. Division of Gastroenterology, Department of Pediatrics, University of California San Diego, La Jolla,

CA, USA.

3. Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA.

4. Division of Infectious Diseases, Department of Pediatrics, University of California San Diego, La Jolla,

CA, USA.

5. Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.

6. Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA.

7. Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA,

USA.

8. Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.

9. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University

of California, San Diego, La Jolla, CA, USA.

#Corresponding author: adswafford@ucsd.edu and dasweeney@health.ucsd.edu

Abstract

Background

Determining the role of fomites in the transmission of SARS-CoV-2 is essential in the hospital setting and

will likely be important outside of medical facilities as governments around the world make plans to ease

COVID-19 public health restrictions and attempt to safely reopen economies. Expanding COVID-19

testing to include environmental surfaces would ideally be performed with inexpensive swabs that could

be transported safely without concern of being a source of new infections. However, CDC-approved

clinical-grade sampling supplies and techniques using a polyester swab are expensive, potentially expose

laboratory workers to viable virus and prohibit analysis of the microbiome due to the presence of

antibiotics in viral transport media (VTM). To this end, we performed a series of experiments comparing

the diagnostic yield using five consumer-grade swabs (including plastic and wood shafts and various head

materials including cotton, polyester, and foam) and one clinical grade swab for inhibition to RNA. For

three of these swabs, we evaluated performance to detect SARS-CoV-2 in twenty intensive care unit

(ICU) hospital rooms of patients with 16 COVID-19+. All swabs were placed in 95% ethanol and further

evaluated in terms of RNase activity. SARS-CoV-2 was measured both directly from the swab and from

the swab eluent.

Results

Compared to samples collected in VTM, 95% ethanol demonstrated significant inhibition properties

against RNases. When extracting directly from the swab head as opposed to the eluent, RNA recovery

was approximately 2-4x higher from all six swab types tested as compared to the clinical standard of

testing the eluent from a CDC-approved polyester swab. The limit of detection (LoD) of SARs-CoV-2

from floor samples collected using the CGp or TMI swabs was similar or better than the CDC standard,

further suggesting that swab type does not impact RNA recovery as measured by SARs-CoV-2. The LoD

for TMI was between 0-362.5 viral particles while PE and CGp were both between 725-1450 particles.

Lastly microbiome analyses (16S rRNA) of paired samples (e.g., environment to host) collected using

different swab types in triplicate indicated that microbial communities were not impacted by swab type

but instead driven by the patient and sample type (floor or nasal).

Conclusions

Compared to using a clinical-grade polyester swab, detection of SARS-CoV-2 from environmental

samples collected from ICU rooms of patients with COVID was similar using consumer grade swabs,

stored in 95% ethanol. The yield was best from the swab head rather than the eluent and the low level of

RNase activity in these samples makes it possible to perform concomitant microbiome analysis.

63
Keywords:

COVID-19, SARS-CoV-2, RT-qPCR, swab, global health

Background

Since its appearance in early December of 2019, Severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has spread to 197

countries resulting in a total of 539,906 deaths and 11,669,259 confirmed cases as of July 8, 2020[1]. As

health officials rush to contain the spread of the disease, federal governments are combating the economic

fallout, and there is a pressing need to reopen the economies albeit safely, gradually, and in stages. Large-

scale testing and contact tracing remain key for controlling viral spread. In addition,; environmental

sampling of microbes can support the epidemiologic investigations of disease outbreaks [2,3] and shows

promise for monitoring SARS-CoV-2. However, there are supply and cost limitations with the products

currently recommended required by the CDC protocol for sample collection supplies. For

example, personal protective equipment, swabs and, viral transport medium (VTM), and personal

protective equipment (PPE) are being depleted in developed nations like the United States, and are in

even shorter supply in resource limited settings including low- and middle-income countries (3). Broad

SARS-CoV-2 surveillance requires microbiologic surface fomite sampling protocols, the efficacy of

which hinges on requires inexpensive, readily available swabs and collection reagents to support the large

sample sizes at geographic scales necessary to inform public health policy., and the growing need for

environmental testing will place additional demands on current swab supplies.

84
The use of the U.S. Centers for Disease Control (CDC)-recommended viral transport media (VTM) places

an additional barrier to efficient and safe deployment of screening and sampling measures. VTM

maintains viral viability and therefore the CDC recommends that all samples be handled in a biosafety

level-2 (BSL-2) laboratory . VTM also contains antimicrobial agents that limit the type of research

studies into likely to interfere with downstream assessment of the microbial context of SARS-CoV-2,

such as microbial relationships with that may enable new insights into viral susceptibility and resistance

as demonstrated by several recent reports [4–6]. Using inactivating sample collection solutions, such as

microbiome assay-compatible alcohols, would increase the number of testing laboratories capable of

performing SARS-CoV-2 screening, and ameliorate the risks associated with sample transport and

processing. Given these considerations, validation of alternative strategies such as self-administered

testing using consumer-grade materials and inactivating storage media is urgently needed.

There are aspects of both the swab and the transport media which must be considered when developing a

testing procedure for SARS-CoV-2. From a microbiome perspective, the primary concern with using

alternative media and consumer-grade materials is the risk of contaminant RNases and/or PCR inhibitors.

The presence of these molecules would increase the false negative rate of SARS-CoV-2 RNA by either

degrading the virus, or interfering with reverse transcription and quantitative polymerase chain reactions

(RT-qPCR) which are the basis for SARS-CoV-2 testing [7]. In addition, the ability to extract the virus

from either the swab or the swab eluent must be elucidated. The fixative property of ethanol could result

in nucleic acids adhering to swab heads, reducing the ability to measure SARS-CoV-2 RNA from the

swab eluent [6]. To fully address these concerns, large screening efforts comparing the recommended and

alternative collection methods are needed. However, given the present scale and urgency of the COVID-

19 pandemic outbreak, limiting this comparison to a small number of viable options would greatly

expedite providing guidance for alternatives to the supply chain this process while minimizing costs. Here

we characterize the suitability of detecting SARS-CoV-2 RNA in experimental conditions as well as

COVID-19 patient and built-environment samples using viral-inactivating storage solutions and

alternative medical-grade and consumer-grade swabs.

111
Materials and Methods

VTM versus EtOH sample comparison

Nasopharyngeal (NP) swabs were collected from COVID-19 positive individuals (n=39) according to CDC

guidelines and were stored in viral transport media (VTM) and transported to the lab on dry ice. For

comparison, sterile polyester-head, plastic-shaft ('PE', BBL Culture swab REF-220135, Becton, Dickinson

and Company) were used to collect nares samples by rotating the dry swab head in the nares for

approximately 10 seconds from lab members, COVID-19 patients (n=11), or healthcare workers (n=11) in

the Hillcrest ICU, and then immediately placed in 95% ethanol (EtOH), and transported to the lab on dry

ice. Eluent nucleic acid extractions were performed on 200 µL of the swab eluent (either VTM or EtOH)

using the Omega Mag-Bind® Viral DNA/RNA 96 Kit (catalog# M6246-03), which only uses chemical

lysis and does not include a bead beating step. For nucleic acid extraction from the swab head, the MagMAX

Microbiome Ultra kit (Cat#A42357, Thermo Fisher Scientific) was used. For the direct comparison of

SARS-CoV-2 extraction efficiency, we extracted EtOH eluent and swab separately from the same samples

of COVID-19 patients (n=24) with approval of the UC San Diego Institutional Review Board under

protocols #150275 and #200613.

127
RT-qPCR for VTM and 95% EtOH comparison using polyester-tipped plastic swabs

SARS-CoV-2 detection was performed following a miniaturized version of the CDC protocol. Each RT-

qPCR reaction contained 4 µL RNA template, 100 nM forward and reverse primers, 200 nM probe, 3 µl

TaqPath (catalog# A15299, Thermo), and RNase-free water to a total reaction volume of 10 µl. All primers

and probes were ordered from IDT (catalog# 10006606). RT-qPCR was performed on the Bio-Rad CFX384

Touch Real-Time PCR Detection System following the CDC thermocycling guidelines. Serial dilutions of

the Hs_RPP30 Positive Control plasmid (catalog# 10006626, IDT) or 2019-nCoV_N_Positive Control

plasmid (catalog# 10006625, IDT) were included to extrapolate human RNase P (Rp) and SARS-CoV-2

copy numbers, respectively. The SARS-CoV-2 N1 marker gene was used for detection and quantitation

[8][9].

138
Validation of use of alternative swabs (testing inhibition of SARS-CoV-2 detection)

The standard swab type approved for use in SARS-CoV-2 detection is a synthetic fiber swab with a plastic

or wire shaft polyester head. In addition to a CDC approved device, we tested an additional five alternative

swabs that included both plastic and wood materials for the shaft and polyester, foam, or cotton materials

for the swab head. The exact devices used were sterile rayon polyester-head, plastic-shaft ('PE', BBL

Culture swab REF-220135, Becton, Dickinson and Company); sterile foam-head, plastic-shaft ('BDF',

Flock PurFlock REF-25-3606-U-BT, Becton, Dickinson and Company); non-sterile cotton-head, plastic-

shaft in use by The Microsetta Initiative ('TMI', SKU#839-PPCS, Puritan Medical Products); non-sterile

cotton-head plastic-shaft consumer-grade ('CGp' Part #165902, CVS Caremark Corp.); non-sterile cotton-

head wooden-shaft consumer-grade ('CGw', Part#858948, CVS Caremark Corp.); and non-sterile cotton-

head, wooden-shaft ('Pu', REF-806-WC, Puritan Medical Products). The goal was to evaluate if detection

of SARS-CoV-2 was reduced with certain swab types from both the eluent (standard protocol) and swab

head directly (new method). A total of six swab types were compared and All swabs were processed

following the standard SARS-CoV-2 protocol provided by the CDC [6]. The six swab types were used:

sterile rayon polyester-head, plastic-shaft ('PE', BBL Culture swab REF-220135, Becton, Dickinson and

Company); sterile foam-head, plastic-shaft ('BDF', Flock PurFlock REF-25-3606-U-BT, Becton,

Dickinson and Company); non-sterile cotton-head, plastic-shaft in use by The Microsetta Initiative ('TMI',

SKU#839-PPCS, Puritan Medical Products); non-sterile cotton-head plastic-shaft consumer-grade ('CGp'

Part #165902, CVS Caremark Corp.); non-sterile cotton-head wooden-shaft consumer-grade ('CGw',

Part#858948, CVS Caremark Corp.); and non-sterile cotton-head, wooden-shaft ('Pu', REF-806-WC,

Puritan Medical Products). To evaluate if the raw swab materials had any background contaminants such

as RNase, which would decrease the sensitivity, we added 600 ng of purified, DNA-free human lung RNA

(Cat#AM7968, Thermo Fisher Scientific) onto each of the six swab types in triplicate and immediately

stored in two storage solutions (500 µL 95% EtOH and 500 µL 91% isopropanol). Separately, two sets of

six, 10-fold serial dilutions of human RNA were included as controls directly.

The same quantity of human RNA (600 ng) along with an equal volume (5 µL) of SARS-CoV-2 RNA was

added to either 95% EtOH (n=3) or 91% isopropanol (n=3) in the presence of 0, 2.5, and 25 µg RNaseA (in

triplicate) to assess any inhibition offered against RNase contaminants. Four negative (swab only) and four

positive (swab + 600 ng spiked human RNA + 5 µL spiked SARS-CoV-2 RNA [~20,000 copies per µL])

controls were included.

Limit of detection comparison of swabs using floor as substrate

To estimate the limit of detection and compare the viral yield across three swab types (PE, CGp, and

TMI), a serial dilution of viral particles was spiked onto floor swabs. In brief, separate 25 cm x 25 cm

areas of the floor from a low-traffic common room inside a building with no SARS-CoV-2 research

activities (i.e., Marine Biology research building at UC San Diego) were swabbed with a total of 24 swabs

per swab type. Swabs were processed in groups of six by swabbing a quarter of that 625-cm^2 space, with

each swab ultimately covering an *ca.* 26-cm^2 area, the similar surface area (25 cm^2) used for detection of

low biomass samples in JPL spacecraft assembly clean rooms based on previous work in the JPL

spacecraft assembly facility [10]. Swabs were then stored at room temperature for *ca.* 1 hr in a 2-mL

deep-well 96-well plate during transport back to a BSL-2 laboratory at UC San Diego. A single serial

dilution of SARS-CoV-2 viral particles [BEI Resources: Cat# 52286, Lot# 70033548] was made at the

following concentrations: 232000, 2320, 1160, 580, 290, 145, and 72.5 viral particles per µL. A total of 5

µL of each dilution, or water as a negative control, was pipetted onto each swab type in triplicate and then

immediately placed into 95% EtOH. Swabs in EtOH were then stored overnight at -80°C until processing.

Upon processing, an additional 24 'no swab' controls were included whereby 5 µL of the dilutions were

dispensed directly into the extraction plate lysis buffer. Samples were processed using the same nucleic

extraction method as described for swab heads above, and eluted in 75 µL of elution buffer. For RT-

qPCR, 5 µL of template was used for each marker N1 and Rp. To address potential issues of non-

normality, total copies were compared across swab types at each individual dilution using Kruskal-Wallis

tests with Benjamini-Hochberg FDR 0.05 post-hoc test.

Patient and hospital environmental sampling

All study patients were hospitalized with clinical concerns for COVID-19 and received standard diagnostic

testing. Study samples were collected from subjects' nares or hospital surfaces using three dry swab types

(PE, TMI, CGp) under the UC San Diego Institutional Review Board protocol #150275 and #200613. Both

nasal samples and hospital surfaces were collected using three dry swab types (PE, TMI, CGp). Nasal

samples were collected by inserting the swab into one nostril to the depth of approximately 2-3 cm and

rotated for 5-10 seconds. Hospital surfaces sampled included the floor inside the patient's room (*ca.* 625-

cm^2 area) and the patient's bedrail. All swabs were immediately placed in a collection tube containing 0.5-

1.0 mL 95% EtOH, stored on dry ice, and processed for RNA or total nucleic acid extraction

(Supplementary Methods).

Extraction and RT-qPCR of hospital swabs and controls

All swab comparison- and hospital samples were processed according to the manufacturer's protocol using

the MagMAX Microbiome Ultra kit (Cat#A42357, Thermo Fisher Scientific), and eluted into 70 µL buffer.

For RT-qPCR, 5 µL sample was processed using the standard SARS-CoV-2 protocol provided by the CDC

(Cat# 2019-nCoVEUA-01[11]).

Microbiome processing and analysis

A subset of 40 samples were processed for 16S rRNA sequencing using established EMP protocols

(https://earthmicrobiome.org/protocols-and-standards/16s/). These included 18 floor samples, 21 nasal

samples, and 1 negative control. Floor samples included all triplicates from the three swab types (PE, TMI,

and CGp) from two patient rooms (patient 7 and 18). The nasal samples included triplicates of all three

swab types from patient 1, triplicates of PE and CGp from patient 7, and triplicates of PE and TMI from

patient 18. The same previously extracted nucleic acid template, which was concurrently used for RT-

qPCR, was used as template for 16S rDNA library generation (amplifying the DNA). Specifically, 0.4 µL

of nucleic acid was processed in 10 µL 16S rRNA PCR reactions following the miniaturized protocol [12]

using the 515f/806r EMP primers, and sequenced on an Illumina MiSeq [13–16]. Samples were then

processed in Qiita (Study ID 13275) [17] and analyzed using the QIIME2 [18,19] [version?] pipeline with

Deblur [20] 1.1.0 as the method of sOTU generation. Samples were visualized in PCoA plots in Qiita using

EMPeror [21]. Beta diversity was calculated using Unweighted Unifrac and compared with PERMANOVA

(999 permutations).

223
Statistics and visualizations

Visualizations and statistical comparisons performed using PRISM 8.0 and the limit of detection

determination were consistent with CDC recommendations whereby samples with a Ct value greater than

40 were omitted [8].

Results

Our experimental design sought to answer three primary questions: whether the efficacy of SARS-CoV-2

detection is influenced by the following three variables: 1) does the swab storage solution (95% EtOH vs

91% isopropanol) impact the sensitivity of detection; 2) which sample fraction, swab head or eluent,

provides better detection fidelity; and 3) does the swab head material type matter? To do this we designed

a series of experiments to compare RNA recovery as measured by RT-qPCR using multiple swab types and

storage solutions. We additionally did environmental sampling in a hospital environment with a subset of

swab types for comparison.

Feasibility of 95% EtOH for sample storage and extraction from use of swab head rather than eluent

To evaluate the feasibility of switching from VTM to a more readily-available, viral-inactivating sample

collection solution, we compared the extraction efficiency of polyester-tipped plastic-shafted

nasopharyngeal (NP) swab samples stored in VTM versus nasal samples collected using CDC-

recommended polyester-tipped plastic-shafted (PE) swabs stored in 95% ethanol (EtOH). When mirroring

the CDC protocol, which calls for extraction from 200 μL of the eluent from VTM surrounding NP swabs,

we had significantly lower recovery of human RNA in 95% EtOH eluent compared to VTM (Figure 1a;

one-way ANOVA with Tukey's multiple comparison, VTM eluent vs. EtOH eluent $p<0.001$). However,

similar levels of human RNA were recovered when extracting from the EtOH-preserved swab head itself

(Figure 1a; one-way ANOVA with Tukey's multiple comparison, VTM vs. EtOH swab $p=0.3$). In a subset

of seven COVID-19 patient nares samples stored in 95% EtOH, we also detected significantly higher

SARS-CoV-2 viral load in RNA extracted from the swab head versus eluent (Figure 1b; one-tailed paired

Student's t-test $p=0.03$).

251
To more quantitatively determine the effects of alcohol-based preservation media, we extracted RNA from

a pure, commercial sample of human RNA added to water, EtOH, or 91% isopropanol, and found no impact

on extraction efficiency (Figure 1c; one-way ANOVA, $p>0.05$). Next, we examined whether alcohol

storage solutions had any protective properties of RNA, specifically a possible inhibitory effect on RNases

that might be present in the environment. If alcohol inhibits the RNaseA, one would expect to see similar

amounts of RNA as without RNaseA added in control experiments. In the presence of abundant RNaseA

added to the solution, 95% EtOH protected both human RNA and SARS-CoV-2 RNA better than 91%

isopropanol. Only a moderate decrease in total RNA recovery was observed, at the most extreme

concentration of 25 mg per reaction, which is equivalent to the standard amount used for RNA removal

during DNA extraction (Figure 1d).

262
Comparison of alternative swab types against standard CDC approved polyester swab

Given that the performance of eluent vs. swab-based extractions in each alcohol may depend on the swab

tip and body composition, we next tested RNA recovery from both the swab head and the surrounding

eluent from a range of medical- and consumer-grade swabs (Methods) (Figure 1e). The RNA yield was

highest from swab heads compared to eluent regardless of the swab type and whether stored in 95% EtOH

(p<0.0001, U=37, Mann-Whitney) or 91% isopropanol (P<0.0001, U=28, Mann-Whitney) (Figure 1e-f).

The storage solution did not impact RNA quality (Supplemental Figure 1b, Mann-Whitney, p>0.05),

although swab type had a minor impact (Supplemental Figure 1c, Kruskal-Wallis p=0.03, KW=12.17)[22].

To compare impacts of various alternative swabs, we normalized the recovery of each test to PE eluent,

indicated by '1' (Figure 1e), which is the standard CDC approved method. Thus, any sample with a value

greater than 1 would indicate an enhanced recovery of RNA, whereby less than 1 indicates a lower recovery

of RNA compared to the standard. The RNA recovery ratio of swab-to-eluent and total yield varied among

swab type (p<0.0001, KW=28.37, Kruskal-Wallis for eluent, and p<0.0001, KW=15.43, Kruskal-Wallis

for swab heads) (Supplemental Figure 2). This difference in performance may relate to the differences in

observed adsorption capacity across swab types (Shapiro-Wilkes p=0.1, w=0.8357; ANOVA p=0.0001,

F=7.5, R^2=0.56). TMI adsorbed the least (84.5 μL, 20.4; mean, SD) followed by plastic shafts (PE: 141 μL,

23.1; CGp: 143.3 μL, 29.9) (Supplemental Figure 3). CGp swabs had the highest recovery of RNA from

the swab head, while TMI swabs had the highest overall recovery of RNA when combining both eluent and

direct swab extractions (Figure 1e, Supplemental Figure 2).

282
SARSs-CoV-2 limit of detection comparison across swab types

We next assessed whether the swab type used would impact the recovery of SARS-CoV-2 and alter the

limit of detection when using non-CDC-recommended swabs (CGp or TMI compared to PE). All negative

controls for floor swabs were indeed negative for SARS-CoV-2 using N1 and N2 (Supplemental Table 1,

Figure 2) and all 'no-swab' controls which only had SARS-CoV-2, were negative for human Rp

(Supplemental Table 1). For the 'no-swab' and TMI swab, SARS-CoV-2 was detected in all of the three

replicates at the lowest input of 362.5 genome equivalents 'GE', whereas the lowest dilution for all three

replicates to be positive for CGp and PE swabs was 1450 GE (Supplemental Table 1, Figure 2a). This

suggests the limit of detection for neat and TMI swabs is likely between 0 and 362.5 GE per reaction

whereas both CGp and PE were less sensitive with an expected limit between 750 and 1450 GE per reaction.

There was a strong correlation between the input or theoretical GE and the measured GE with slopes all

greater than 0.95 and the R^2>0.96. Despite TMI appearing to have the best overall performance in SARSs-

CoV-2 detection followed by PE and then CGp, the total viral yield did not differ across swab types at the

lowest dilution of 362.5 (P>0.05, Kruskal-Wallis test) (Figure 2a). Specifically, multiple post-hoc

comparisons showed that variation across swab-type only existed at the highest concentration (116,000 GE)

with the TMI swabs having a higher viral recovery compared to PE swabs (P=0.04, KW=7.21) (Figure 2).

Rp yield was also compared across swab types and across viral inputs to characterize the variation in input

biomass. For each swab type, human Rp gene was equally detected across the titrations indicating the swab

method was sufficiently controlled (Supplemental Figure 4a). Swab type, however, did suggest that the Rp

gene was highest in the PE swab as compared to the CGp and TMI swabs (Kruskal-Wallis: P<0.0001,

KW=41.41) (Supplemental Figure 4b). This result suggests that PE swabs may adsorb more biomass.

However, when we compared the variation in Cq values of hospital samples of nares and floor from the

same hospital using PE swabs, we observed Rp values that varied over six orders of magnitude

(Supplemental Figure S5), much greater than the three orders of magnitude observed across swab types.

Specifically, for floor samples, the Rp yield (copies per extraction) range across swab types was 149-3368

copies for PE, 0-3980 for CGp, and 0-207 for TMI.

Hospital proof of concept study

Based on the results from these initial experiments, we conducted a proof-of-concept study in the clinical

setting by performing RT-qPCR for the SARS-CoV-2 N1 amplicon and human RNase P gene on RNA

extracted from the swab head of nasal samples collected using TMI and/or CGp swabs alongside the

recommended PE swabs. Of the 20 participants sampled, 16 tested positive for SARS-CoV-2 at admission

and were designated as COVID-19(+). The average time from diagnosis to sampling was *ca.* 4.2 days, with

a NP swab test occurring within 72 hours of the time of nasal sampling. Of the 12 nasal samples using the

PE swab preserved in EtOH from COVID-19(+) patients, nine were positive for the presence of SARS-

CoV-2 or a false negative rate of 25% (Figure 3a) compared to 14/16 SARS-CoV-2 positive NP swabs for

the same group of patients, a false negative rate of 12.5%. For CGp and TMI swabs, 8/12 and 5/10 were

positive for nares, respectively (Figure 3a). These rates of false negatives are similar, as compared to the

37.5% false negative rate reported for plastic-shafted polyester-tipped nasal swabs collected in VTM and

extracted from the eluent (Wang et al. 2020). As the degree of viral shedding is known to vary over the

course of the disease [23], we compared the performance in the subset of COVID-19(+) patients with an

NP-positive swab result within 72 hours of the time of sampling, and observed reduced false negative rates

of 18.2% (PE), 25% (TMI), and 30% (CGp). We next compared success rates across swab samples from

the built environment. On the floor samples, the CGp had the highest success rate at 75% in detection of

SARSs-CoV-2 from SARSs-CoV-2 positive patient rooms whereas PE detected SARSs-CoV-2 in 63% of

rooms, and TMI in 44% of rooms (Figure 3a). Bedrail samples had the lowest frequency of detection, 5/16

(31%), for each swab type (Figure 3a). For SARSs-CoV-2 negative patients admitted to the same hospital

for other reasons, all nares and bedrail samples were negative, whereas one floor sample using the PE swab

detected SARSs-CoV-2 (Figure 3b).

The observed differences in detection among nares and environmental samples, taken in context of results

that Since our previous experiment demonstrates that suggest swab type does not impact SARSs-CoV-2

detection, this suggests that variation in sample collection from the nares and other environmental samples

has an important role in detection sensitivity. When swabbing an environmental surface or body site (i.e.,

nares), there is inherent variation in the swabbing event which can be attributed both to stochastic

differences in biomass (human cells, dust, etc.) and the overall assay (nucleic acid extraction and RT-

qPCR). To evaluate if certain sampling locations or swab types were more variable than others, we

calculated the intra-assay coefficient of variance (CV) of the Cq values. The CV was significantly higher

in patient nasal samples compared to control (RNA spike-in) samples (P=0.0018), with a median difference

in variance of 2.5 (Supplemental S6a). Swab types also demonstrated an effect with CGp and PE differences

being significant as compared to the control (P=0.0012) (Supplemental Figures S6b).

Microbiome analysis

To determine the feasibility of co-opting nucleic acid for microbiome processing, we processed a subset of

samples (n=40) spanning a total of three patients, two sample types (floor and nasal) and the three swab

types. After processing with Deblur, the total number of reads per sample were compared (Figure 4a). Read

counts were highly variable across sample types and for each patient but were consistent within the swab

types for each comparison. For floor samples in patient room 18, PE swabs had the highest number of reads

followed by TMI and CGp. For nasal samples however, patient 1 had the higher read counts from TMI

while patient 7 and 18 both showed slightly lower read counts for PE swabs as compared to alternative

swabs. The differences were minor however and are primarily differentiated by patient room (Figure 4a).

After rarifying to 5000 reads a PCoA plot was generated from using Unweighted UniFrac distances (Figure

4b). Samples which were collected using different swab types clustered together when controlling for

patient room and sample type, suggesting indicating that the swab type used does not have a negative impact

on microbiome analysis (Figure 4b). When analyzing all samples together, sample_type (floor vs nasal)

and patient number (7 vs 18) were both significant drivers of the microbiome community (sample_type:

PERMANOVA n=24, group=2, P=0.001, Fstat=6.94; patient_num PERMANOVA n=24, group=2,

P=0.001, Fstat=6.92) whereas swab type did not have an effect (P=0.164). Distances between swab types

were lower than distances between patients for both floor (Supplemental Figure S7a) and nasal

(Supplemental Figure S7b) samples, with patient 7 exhibiting higher variation than patient 18. Floor

samples generally had a higher microbial diversity compared to nasal swabs, with *Staphylococcus*,

Corynebacterium, *Pseudomonas*, *Streptococcus*, and Enterobacteriaceae being the more dominant taxa.

Nasal samples however were mostly enriched by either *Staphylococcus* or *Corynebacterium*, with patient

7 having a higher abundance of *Lawsonella* (Figure 4c).

367
Discussion

When assessing whether it will be possible to adapts and switch collection methodology to enable more

affordable, more widely available, and more inter-assay compatible collection methods for SARS-CoV-2

monitoring, it is key to understand the feasibility of using both alternative swabs and sample storage

solutions. Here we provide evidence that the variation observed in a given SARSs-CoV-2 experiment is

primarily driven by the time and method of sample collection rather than by the swab type, storage solution,

and subsequent extraction and RT-qPCR. When using alcohol-based storage solutions, we demonstrate that

the nucleic acid or viral particles tend to become enriched on the swab head rather than the eluent and thus

we recommend extracting directly from the swab head itself. We demonstrate that RNA can be successfully

extracted from consumer-grade swabs stored in alcohol without compromising RNA integrity or yield. Of

note, wooden-shafted swabs performed poorly only when extracting from the eluent, suggesting that RNA

adsorption onto the shaft, rather than RT-qPCR inhibitors, may be the source of interference with current

eluent-based testing methods for this swab type. As cotton-tipped swabs and alcohol-based storage

solutions are compatible with standard microbiome- and metabolome analyses not feasible with VTM, these

alternatives could enable more widespread assessment of the microbial context of SARS-CoV-2 RNA in

human and environmental samples, including associated microbiome features.

384
We also provide preliminary evidence that nasal samples collected using more widely available, consumer-

grade, cotton-tipped swabs can be used to detect SARS-CoV-2 in the clinical setting. As cotton-tipped TMI

swabs had only a marginally reduced performance compared to CDC-compliant PE swabs for nasal samples

compared to NP results, these swabs provide the potential as an attractive alternative for methods such as

metabolomics that are complicated by the background from incompatible with polyester-tipped swabs, as

well as suggesting the expanding the pool of available medical-grade collection consumables could be

expanded. Notably, this variation is less than that observed when comparing different methods for assessing

the presence of SARS-CoV-2. Larger-scale testing will be needed to expand and confirm these findings,

but our data suggests that these two swab types, in either 95% EtOH or isopropanol, would provide a

valuable starting point.

395
When considering environmental sampling, our data suggest that TMI and CGp swabs may outperform or

at least are similar to, CDC-compliant PE swabs for collecting samples to detect SARS-CoV-2 from floor

samples. We provide molecular evidence demonstrating the feasibility of detecting SARs-CoV-2 from floor

samples with a limit of detection (*ca.* 362.5 copies per extraction for TMI) and (750-1450 copies per

extraction for CGp and PE) similar to that of other published studies (500 copies per extraction) [24].

Additional testing using pre-wetted swab heads, as performed in other built-environment studies [25–29],

is warranted to determine if this would improve the ability of all swab types to detect SARS-CoV-2 in the

hospital room environment. The detection of SARS-CoV-2 on *ca.* 50% of COVID-19(+) participants'

bedrails and *ca.* 75% of floors, as well as the detection of SARS-CoV-2 on the floor of one non-COVID

patient, suggests increased cleaning measures may need to be taken. Indeed, the floor may be a potentially

important reservoir for viral exposure, as shoe-covers are not currently recommended by the CDC.

However, additional testing is needed to determine whether viable virus particles remain on these surfaces.

Since detection largely does not differ across swab types, this suggests that differences seen in the

quantitation of SARSs-CoV-2 in the clinic in a given floor or nasal sample is due to variation in the

swabbing event itself rather than a molecular processing problem. Because of this, we recommend the need

for standardization in medical devices used to collect both nasal and environmental samples specific to

SARSs-CoV-2 to improve overall accuracy. Lastly, our efforts to quantify the total noise in a given

sampling event and sample processing itself demonstrate how variation in the act of swabbing combined

with sample processing may lead to variance and at times lower than expected specificity.

415
Secondary infections are an important and significant contributing factor to morbidity and mortality in

COVID-19 patients [30,31]. With metagenomics assays becoming more common for infectious disease

diagnostics in the clinic [32–34], developing molecular methods which enable simultaneous viral detection

and metagenomic analysis is critical for understanding disease progression in at-risk populations. Since the

storage method is a critical step in preserving microbiome integrity with 95% ethanol as a stable solution

[35], our results further demonstrate and open the door for multi-omics processing and analysis of SARSs-

CoV-2 samples.

423
In summary, our results suggest detection of SARS-CoV-2 RNA in the environment could be performed

using less expensive, consumer-grade materials and alcohol-based storage solutions. With the materials

examined in this study, it is further conceivable that patients could collect samples from themselves, their

environments at home, or their place of work, dramatically expanding the ability to deploy widespread

methods for monitoring and predicting outbreak events. Additional confirmatory studies using consumer-

grade swabs would greatly support COVID-19 screening worldwide, particularly in resource-limited

communities.

431
Acknowledgements:

We thank research participants who donated samples, the health care professionals who assisted in the

collection of samples, and Alison Vrbanac, Louis-Felix Nothias-Scaglia, and Shi Huang for assistance in

transportation and Dominic Nguyen for sampling kit preparation. This research benefited tremendously

from lessons learned and techniques developed in the Sloan Microbiology of the Built Environment (MoBE

program). We thank Stanley T. Motley for early discussion on nucleic acid stability, Sandrine Miller-

Montgomery for guidance in RT-qPCR analyses. We thank Thomas F. Rogers and Nathan Beutler for

providing the SARS-CoV-2 viral RNA used as a control in this study and David Pride for supplying samples

from NP swabs in VTM for our comparisons.

441
This work was supported by the UC San Diego Center for Microbiome Innovation (CMI). JJM is supported

by the National Science Foundation Center for Aerosol Impacts on Chemistry of the Environment

#1801971. CM is supported by NIDCR NRSA F31 Fellowship 1F31DE028478-01. PBF is partially funded

through trainee support from Sanitarium Health and Wellbeing in partnership with the CMI. DM is partially

funded by support from Danone Nutricia Research in partnership with the CMI. JPS is supported by NIH-

SD-IRACDA (5K12GM068524-17) and USDA-NIFA (2019-67013-29137).

References:

1. Mediterranean 828 Deaths Eastern, Cases 98, Europe 664 Deaths, Cases 2. 827 789, Pacific 224 Deaths
Western, Cases 31 749, et al. Situation in numbers (by WHO Region). Available from:
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200708-covid-19-sitrep-
170.pdf?sfvrsn=bca86036_2

2. Gilbert JA, Stephens B. Microbiology of the built environment. Nat Rev Microbiol. 2018;16:661–70.

3. CDC Background F. Environmental Sampling [Internet]. 2019 [cited 2020 Jul 9]. Available from:
https://www.cdc.gov/infectioncontrol/guidelines/environmental/background/sampling.html

4. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention SOP#: DSR-
052-02- PREPARATION OF VIRAL TRANSPORT MEDIUM [Internet]. Centers for Disease Control
and Prevention- PREPARATION OF VIRAL TRANSPORT MEDIUM. 2020 [cited 2020 Apr 24].
Available from: https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf

5. Kalantar-Zadeh K, Ward SA, Kalantar-Zadeh K, El-Omar EM. Considering the Effects of Microbiome
and Diet on SARS-CoV-2 Infection: Nanotechnology Roles. ACS Nano [Internet]. 2020; Available from:
http://dx.doi.org/10.1021/acsnano.0c03402

6. Bergner LM, Orton RJ, da Silva Filipe A, Shaw AE, Becker DJ, Tello C, et al. Using noninvasive
metagenomics to characterize viral communities from wildlife. Mol Ecol Resour. 2019;19:128–43.

7. Oropharyngeal 1., Swabs N. Collection of Upper Respiratory Tract Specimens. Available from:
https://www.cdc.gov/urdo/downloads/SpecCollectionGuidelines.pdf

8. CDC/DDID/NCIRD/ Division of Viral Diseases. CDC 2019-Novel Coronavirus (2019-nCoV) Real-
Time RT-PCR Diagnostic Panel. 2020; Available from: https://www.fda.gov/media/134922/download

9. Marx V. Coronavirus jolts labs to warp speed. Nat Methods. 2020;17:465–8.

10. Minich JJ, Zhu Q, Janssen S, Hendrickson R, Amir A, Vetter R, et al. KatharoSeq Enables High-
Throughput Microbiome Analysis from Low-Biomass Samples. mSystems [Internet]. 2018;3. Available
from: http://dx.doi.org/10.1128/mSystems.00218-17

11. CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention.
2020 [cited 2020 Apr 21]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-
primer-probes.html

12. Minich JJ, Humphrey G, Benitez RAS, Sanders J, Swafford A, Allen EE, et al. High-Throughput
Miniaturized 16S rRNA Amplicon Library Preparation Reduces Costs while Preserving Microbiome
Integrity. mSystems [Internet]. 2018;3. Available from: http://dx.doi.org/10.1128/mSystems.00166-18

13. Apprill A, McNally S, Parsons R, Weber L. Minor revision to V4 region SSU rRNA 806R gene
primer greatly increases detection of SAR11 bacterioplankton [Internet]. Aquatic Microbial Ecology.
2015. p. 129–37. Available from: http://dx.doi.org/10.3354/ame01753

14. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et al. Global
patterns of 16S rRNA diversity at a depth of millions of sequences per sample [Internet]. Proceedings of
the National Academy of Sciences. 2011. p. 4516–22. Available from:
http://dx.doi.org/10.1073/pnas.1000080107

15. Walters W, Hyde ER, Berg-Lyons D, Ackermann G, Humphrey G, Parada A, et al. Improved
Bacterial 16S rRNA Gene (V4 and V4-5) and Fungal Internal Transcribed Spacer Marker Gene Primers
for Microbial Community Surveys. mSystems [Internet]. 2016;1. Available from:
http://dx.doi.org/10.1128/mSystems.00009-15

16. Parada AE, Needham DM, Fuhrman JA. Every base matters: assessing small subunit rRNA primers
for marine microbiomes with mock communities, time series and global field samples. Environ
Microbiol. 2016;18:1403–14.

17. Gonzalez A, Navas-Molina JA, Kosciolek T, McDonald D, Vázquez-Baeza Y, Ackermann G, et al.
Qiita: rapid, web-enabled microbiome meta-analysis. Nat Methods. 2018;15:796–8.

18. Estaki M, Jiang L, Bokulich NA, McDonald D, González A, Kosciolek T, et al. QIIME 2 Enables
Comprehensive End-to-End Analysis of Diverse Microbiome Data and Comparative Studies with
Publicly Available Data. Curr Protoc Bioinformatics. 2020;70:e100.

19. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible,
interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol.
2019;37:852–7.

20. Amir A, McDonald D, Navas-Molina JA, Kopylova E, Morton JT, Zech Xu Z, et al. Deblur Rapidly
Resolves Single-Nucleotide Community Sequence Patterns. mSystems [Internet]. 2017;2. Available from:
http://dx.doi.org/10.1128/mSystems.00191-16

21. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: a tool for visualizing high-
throughput microbial community data. Gigascience. 2013;2:16.

22. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA
integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3.

23. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper
Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382:1177–9.

24. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and
efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat Microbiol [Internet]. 2020;
Available from: http://dx.doi.org/10.1038/s41564-020-0761-6

25. Lax S, Cardona C, Zhao D, Winton VJ, Goodney G, Gao P, et al. Microbial and metabolic succession
on common building materials under high humidity conditions. Nat Commun. 2019;10:1767.

26. Richardson M, Gottel N, Gilbert JA, Lax S. Microbial Similarity between Students in a Common
Dormitory Environment Reveals the Forensic Potential of Individual Microbial Signatures. MBio
[Internet]. 2019;10. Available from: http://dx.doi.org/10.1128/mBio.01054-19

27. Lax S, Sangwan N, Smith D, Larsen P, Handley KM, Richardson M, et al. Bacterial colonization and
succession in a newly opened hospital. Sci Transl Med. 2017;9.

28. Wood M, Gibbons SM, Lax S, Eshoo-Anton TW, Owens SM, Kennedy S, et al. Athletic equipment
microbiota are shaped by interactions with human skin. Microbiome. 2015;3:25.

29. Lax S, Smith DP, Hampton-Marcell J, Owens SM, Handley KM, Scott NM, et al. Longitudinal
analysis of microbial interaction between humans and the indoor environment. Science. 2014;345:1048–
52.

30. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign:
Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit
Care Med. 2020;48:e440–69.

31. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based
on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–8.

32. Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, et al. Metagenomic sequencing with
spiked primer enrichment for viral diagnostics and genomic surveillance. Nat Microbiol. 2020;5:443–54.

33. Wilson MR, Sample HA, Zorn KC, Arevalo S, Yu G, Neuhaus J, et al. Clinical Metagenomic
Sequencing for Diagnosis of Meningitis and Encephalitis. N Engl J Med. 2019;380:2327–40.

34. Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet. 2019;20:341–55.

35. Song SJ, Amir A, Metcalf JL, Amato KR, Xu ZZ, Humphrey G, et al. Preservation Methods Differ in
Fecal Microbiome Stability, Affecting Suitability for Field Studies. mSystems [Internet]. 2016;1.
Available from: http://dx.doi.org/10.1128/mSystems.00021-16

546
547

Figure 1. Validation of alternative swabs and storage buffer (95% EtOH and 91% isopropanol) in

RNA recovery and detection of COVID-19.

a) Human RNAse P gene (Rp) amplification was used to compare nucleic acid extraction efficiency across

sample processing methods. Clinical gold-standard polyester-tipped plastic-shaft NP swabs stored in VTM

and extracted from 200 µL of eluent (left, n=39) have significantly higher copy numbers compared to 200

µL EtOH eluent from PE nares swabs (middle, n=22), but not when extracted from the EtOH-preserved

swab head (right, n=18). One-way ANOVA with Tukey's multiple comparison VTM eluent vs EtOH eluent

p=<0.001, EtOH eluent vs EtOH swab p<0.001, VTM vs EtOH swab p = 0.266. **b)** Extrapolated viral RNA

copy number from COVID-19 positive nares samples collected with BD polyester swabs in the hospital

stored in 95% EtOH and extracted from either the eluent or swab from the same sample (n=24, one-tailed

paired Student's T-test p=0.032). **c)** Proportion of RNA recovered across three storage buffers: None, 95%

EtOH, and 91% isopropanol using commercial human RNA added to storage buffers (ns, one-way ANOVA

p>0.05). **d)** Evaluation of RNaseA inhibition by 95% EtOH (grey) and 91% isopropanol (blue) using either

the human Rp or SARS-CoV-2 N1 primer set on control RNA added to each solution (unpaired t-tests of

95% EtOH vs 91% Iso per each marker at 0, 2500, 25000 ng RNaseA). **e)** Comparison human RNA

recovery across six swab types (PE=polyester 'commercial', BDF=BD foam 'commercial', TMI=BD TMI

'commercial', CGp=plastic 'consumer-grade', Pu=Puritan 'commercial', CGw=wood 'consumer-grade'),

extracted from 200μL eluent (blank bar) or the swab head. Recovery for each swab type is normalized to

the CDC recommended method (eluent from PE swab). A '2' would indicate there was 2x more RNA

recovered whereas a 0.5 would indicate a 50% reduction in RNA recovery. **f)** Total RNA copies per

extraction for all samples which are grouped by sample-type (eluent or swab head) and storage buffer (95%

EtOH or 91% isopropanol). Pairwise comparisons performed within sample-type (not significant) and

across sample-type controlling for storage buffer (Mann-Whitney, U=test statistic).

Figure 2. Limit of detection of SARs-CoV-2 viral particles across swab types

(Polyester 'PE', CGp, and TMI). "Noswab" refers to direct extraction of viral particles. a) Comparisons of total RNA recovery per extraction across swab types including 'noswab' performed at each dilution (Kruskal Wallis test). Comparison of (theory input Genome Equivalents 'GE') to measured GE of triplicates (mean, SEM) by RTqPCR of SARs-CoV-2. Non-linear regression analysis of each dilution series for noswab, PE, CGp, and TMI swabs.

Figure 3: Comparison of CDC approved PE swabs, consumer-grade CGp and bulk TMI swab congruence compared to clinical-grade hospital tests using polyester-tipped plastic shafted NP swabs for twenty participants in the clinical setting. a) SARs-CoV-2 positive patients (n=16) sampled with three swab types across three environments: nares, floor, and bedrail. '+' samples (dark grey = PE, red = CGp, blue = TMI) refer to samples which tested positive for SARs-CoV-2 out of the total samples tested for that particular swab type (light grey bar). Percentage of positive tests per swab type are below x axis for each environmental sample. b)   SARs-CoV-2 negative patients (n=4) with three swab types across three environments: nares, floor, and bedrail. Same nomenclature as above.

Figure 4. Microbiome 16S rRNA sequencing validation across sample types, patients, and swab types.

a) Total number of reads per sample (40 samples sequenced) after processing through deblur pipeline

stratified by sample type (floor 'square' vs nasal 'circle'), patient number (1, 7, and 18) and colored by

swab type (PE = grey, CGp = red, TMI = blue). Error bars represent median, IQR for triplicate biological

replicates per sample. b) Unweighted UniFrac PCoA plot of samples rarified to 5000 reads. Enlarged

samples (2x) indicate patient 7 whereas (1x) indicates patient 18. Swab types are colored (PE = grey, CGp

= red, TMI = blue) and shapes (floor 'square' vs nasal 'circle') indicate sample type. Grey dotted line goes

around each patient. c) Stacked bar plot collapsed at genera level with top ten abundant genera labeled in

the legend.

Supplementary Figures and Legends

618 **Supplemental Table 1.**

Supplemental Table. SARs-CoV-2 Limit of detection: total quantified copies of SARs-CoV-2 (N1 or N2) and human Rp across swab types.

N1

	noswab			PE			CGp			TMI		
0	0	0	0	0	0	0	0	0	0	0	0	0
362.5	1683	749	782	866	0	203	0	600	1539	195	146	173
725	420	599	713	0	2213	752	1585	1175	0	1204	859	755
1450	1704	1722	1665	209	946	2411	1390	1618	2572	1021	3147	1071
2900	4305	3868	3157	1432	2801	4794	4053	2834	2153	2166	4646	4533
5800	7598	6897	8862	3819	8958	5086	5836	10027	7527	12332	10290	10227
11600	19177	14181	13316	11752	11062	11885	20925	10598	13416	17761	18618	15658
116000	138318	121286	151498	104301	139976	94119	163019	111423	138201	212959	233003	172233

N2

	noswab			PE			CGp			TMI		
0	0	0	0	0	0	0	0	0	0	0	0	0
362.5	218	0	133	419	0	125	0	0	643	420	131	289
725	719	474	345	308	458	127	217	222	0	356	484	489
1450	263	1356	371	170	345	1099	1550	633	889	1023	1626	61
2900	1536	2525	781	622	1004	1228	1694	1289	937	1587	1146	1371
5800	2350	2764	3261	2718	3527	1733	2924	6110	2246	4861	5149	3254
11600	5230	5572	6646	5569	4899	5883	6011	3656	4922	8808	8611	7388
116000	49810	53165	57606	43923	66597	43910	46084	41405	50328	93101	102074	61855

Rp

	noswab			PE			CGp			TMI		
0	0	0	0	521	462	391	347	86	66	0	79	0
362.5	0	0	0	1861	737	283	164	263	185	130	83	0
725	0	0	0	723	3368	921	67	81	0	207	0	0
1450	0	0	0	283	426	499	0	0	377	135	198	147
2900	0	0	0	1254	479	222	194	97	422	0	156	0
5800	0	0	0	252	873	491	0	220	0	97	0	0
11600	0	0	0	149	526	1112	203	426	220	52	77	143
116000	0	0	0	330	798	1047	3980	0	256	117	97	0

Supplemental Figure 1. Impacts of storage solution or swab type on RNA quality as measured by RNA Tapestation High Sensitivity kit.

a) All direct-swab extracted RNA grouped by storage buffer and swab type. b) Samples grouped by storage buffer, no significant difference in RNA integrity number (RIN) values between storage buffers (95% EtOH vs. 91% isopropanol) (Mann-Whitney). c) Swab extracts grouped by swab type only and compared to determine if swab type has an impact on RNA quality (Kruskal-Wallis test).

Supplemental Figure 2. Impacts of sample-type (eluent vs. swab head) on RNA recovery by swab

used.

Comparison human RNA recovery across six swab types (PE=polyester 'commercial', BDF=BD foam

'commercial', TMI=BD TMI 'commercial', CGp=plastic 'consumer-grade', Pu=Puritan 'commercial',

CGw=wood 'consumer-grade'), **a)** extracted from 200 µL eluent or **b)** swab head (Group comparison using

Kruskal-Wallis)

Supplemental Figure 3. Adsorption volumes per swab type.

Samples tested for normality using Shapiro- Wilke test (not significant, P=0.12, W=0.8357).

659 **Supplemental Figure 4. Total variation of human Rp gene detected from floor samples in limit of**

660 **detection experiment.** a) Variation of Rp across swab types and subsequent dilutions. b) total yield of

661 human Rp across aggregated swab types.

662
663

Supplemental Figure 5. Variation of human Rp gene amplification across swab types.

(left) Surface swabs were collected from the floor of a laboratory to compare efficiency across swab types; consumer-grade cotton (CGp), The Microsetta Initiative cotton swabs (TMI), and polyester (PE). (right) PE surface swab samples were collected with the same protocol in the hospital. The variation across hospital samples is greater than the variation among swab types.

673
674
675

Supplemental Figure 6. Intra-assay variability compared across positive controls, sample _types, and swab types.

a) Coefficient of variance calculated across pairwise swabs taken within each room/patient replicate and then distributions compared for bedrail, floor, nasal swab, and nasal eluent samples along with positive controls. b) The CV was also grouped and compared by swab type.

684
685 **Supplemental Figure 7.** Comparison of 16S rRNA microbial composition of paired patient and sample

686 type samples collected using different swabs (in triplicate) using Unweighted UniFrac PCoA plot. a) floor

687 samples, b) nasal samples. Swab types: square = PE, circle = CGp, star = TMI.

688
689